Class / Patent application number | Description | Number of patent applications / Date published |
514252170 | The polycyclo ring system is quinazoline (including hydrogenated) | 77 |
20080207632 | PROTEIN KINASE INHIBITORS - Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer, such as Aurora kinase-expressing cancers and Axl kinase-expressing cancers. Compounds of the invention have the following structure: | 08-28-2008 |
20080293735 | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes - The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of dopaminergic neuronal to noradrenergic neuronal activity within the central nervous system and particularly the hypothalamus of the central nervous system of the patient. | 11-27-2008 |
20090042900 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY -
2,4-Diaminoquinazolines of formula (I)
| 02-12-2009 |
20090048265 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE - Antitumor compounds based on the α1-adrenoceptor antagonist, doxazosin, as well as compositions and methods of use. The disclosed compounds induce apoptosis in cancer cells. | 02-19-2009 |
20090062299 | DEUTERIUM-ENRICHED DOXAZOSIN - The present application describes deuterium-enriched doxazosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090062300 | DEUTERIUM-ENRICHED PRAZOSIN - The present application describes deuterium-enriched prazosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090062301 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JA K3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS - The present invention relates to a pharmaceutical combination comprising at least one PKC inhibitor, in particular indolylmaleimide derivatives, and at least one JAK3 kinase inhibitor and the uses of such a combination e.g. in autoimmune diseases, e.g. in preventing or treating type I diabetes mellitus and disorders associated therewith, or in transplantation. | 03-05-2009 |
20090076022 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors. | 03-19-2009 |
20090076023 | Local Anesthetic Methods and Kits - Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist. | 03-19-2009 |
20090099196 | Chemical Process - The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such as a difumarate salt and a trihydrate and to pharmaceutical compositions containing such crystalline forms. | 04-16-2009 |
20090131450 | USE OF PKC INHIBITORS IN DIABETIC COMPLICATIONS - The present invention pertains to the use of a PKC inhibitor in the manufacture of a medicament in the treatment or prevention of diabetic complications. | 05-21-2009 |
20090163509 | Method for healing a wound using an alpha-adrenergic antagonist - A method for healing a wound comprising the step of topically administering a wound healing composition to a wounded area, wherein the wound healing composition comprises a first medicament characterized as an alpha-adrenergic antagonist and pharmaceutically acceptable salts thereof. | 06-25-2009 |
20090170865 | Treatment of Prostate Cancer with Angiogenesis-Targeting Quinazoline-Based Anti-Cancer Compounds - Provided is a method of inhibiting the growth of prostate cancer cells comprising administering an effective amount of DZ-50 (2-[4-biphenyl-4-sulfonyl)-piperazin-1-yl]-6,7-diisopropoxyquinazolin-4-yl-amine) to a patient in need thereof. In another aspect, a method is provided for inhibiting the initiation of prostate cancer comprising administering an effective amount of DZ-50 to a patient in need thereof. In yet another aspect, a method is provided for inhibiting the formation of a prostate tumor-derived metastatic lesion comprising administering an effective amount of DZ-50 to a patient in need thereof. In any of the aforementioned methods, a quinazoline-based drug which induces apoptosis of a prostate cancer cell may be coadministered with DZ-50. Also provided is a composition comprising DZ-50, a quinazoline-based drug which induces apoptosis of a prostate cancer cell, and a pharmaceutically acceptable carrier. | 07-02-2009 |
20090203708 | NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - Disclosed herein are novel substituted-1H-quinazoline-2,4-dione derivatives, a preparation method thereof, and a pharmaceutical composition containing the same. The novel substituted-1H-quinazoline-2,4-dione derivatives are excellent in binding affinity and selectivity for 5-HT6 receptors over other receptors, inhibit serotonin(5-HT)-stimulated cAMP accumulation, and disrupt apomorphine(2 mg/kg, i.p.)-induced hyperactivity in rats. Thanks to these effects, the derivatives are useful in the treatment of 5-HT6 receptor-related central nervous system diseases. | 08-13-2009 |
20090247540 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES - Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer. | 10-01-2009 |
20090258882 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors - The invention relates to compounds of the formula I, | 10-15-2009 |
20090270410 | BENZAZOLE ANALOGUES AND USES THEREOF - The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, | 10-29-2009 |
20090291961 | COMBINATION OF AN MEK INHIBITOR AND THE SRC KINASE INHIBITOR AZD0530 FOR USE IN THE TREATMENT OF CANCER - The invention relates to a combination for use in the treatment of cancer comprising a MEK inhibitor and the Src kinase inhibitor AZD0530. | 11-26-2009 |
20090312342 | Quinazolines useful as modulators of ion channels - The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 12-17-2009 |
20090312343 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS - The invention concerns quinazoline derivatives of the Formula I: | 12-17-2009 |
20090318463 | Indolylmaleimide Derivatives - Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer. | 12-24-2009 |
20100004256 | HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES - Heteroaryl-fused macrocyclic 2,4-diaminopyrimidine compounds of formula (I) | 01-07-2010 |
20100029672 | METHOD OF TREATING LIVER DISEASE - Treating diseased or damaged tissue, particularly the liver, using stem cells. The hepatic stem cell population of a subject suffering from disease or damaged tissue can be expanded by administering at least one regulator of the sympathetic nervous system. The regulator can be an adrenoceptor agonist or antagonist, adrenoceptor antagonists, prazosin, being particularly preferred. The invention also includes the use of agents which mobilize stem cells in the manufacture of medicaments for the treatment of diseased or damaged tissue. | 02-04-2010 |
20100029673 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE - The invention relates to a method for the production of an anti-cancer effect or a method for the treatment of a sold tumour disease by administration of an anti-angiogenic agent selected from 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline and 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline and pharmaceutically-acceptable acid-addition salts thereof, in combination with a Src kinase inhibitor selected from 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline and pharmaceutically-acceptable acid-addition salts thereof. | 02-04-2010 |
20100093749 | COMPOUNDS - The invention provides acid addition salts of 3-(1.H.-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione, crystalline forms thereof, processes for the preparation thereof, pharmaceutical compositions comprising them and uses thereof in therapeutic treatment. | 04-15-2010 |
20100113468 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS - The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. | 05-06-2010 |
20100160338 | BENZENESULFONAMIDE MODULATORS OF ALPHA-1A ADRENERGIC RECEPTORS - The present invention relates to new benzenesulfonamide modulators of alpha-1A adrenergic receptors, pharmaceutical compositions thereof, and methods of use thereof. | 06-24-2010 |
20100168123 | AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: | 07-01-2010 |
20100179162 | Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide - Crystalline forms of the sulfate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the sulfate salt are characterized by a variety of properties and physical measurements. As well, methods of producing the sulfate salts, and using such salts to inhibit excessive tyrosine kinase activity in subjects to treat a number of diseases including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer (e.g., leukemia such as acute lymphocytic leukemia), glomerulosclerosis fibrotic diseases and inflammation, and general treatment of cell-proliferative diseases, are also discussed. | 07-15-2010 |
20100210663 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity - Hybrid compounds containing an aminotetralin moiety or a heterocyclic and/or open chain analog thereof linked through an alkylene group to an aryl ring system-substituted piperidiene moiety exhibit high levels of CNS activity, in some cases exhibiting especially high relative binding efficiencies between D3 and D2 dopaminergic receptor subtypes. | 08-19-2010 |
20100216808 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS - Pyrazolo-quinazoline derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 08-26-2010 |
20100222359 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING QUINAZOLINEDIONE DERIVATIVES - The present invention provides quinazolinedione derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, depression and dementia. | 09-02-2010 |
20100273808 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CAR- BOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS - This invention provides a compound of formula (I): | 10-28-2010 |
20100273809 | METHOD AND COMPOSITION FOR TREATING AN ALPHA ADRENOCEPTOR-MEDIATED CONDITION - Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions. | 10-28-2010 |
20100280042 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS - The invention concerns quinazoline derivatives of Formula (I) wherein each of Q | 11-04-2010 |
20110028488 | COMBINATION PRODUCT COMPRISING SRC KINASE INHIBITOR AZDO530 AND AN ANTIOESTROGEN OR EGFR-TK-INHIBITOR - The invention relates to a combination for use in the synergistic treatment of breast cancer comprising an antioestrogen and the Src kinase inhibitor AZD0530, a combination for the synergistic treatment of cancer comprising an EGFR TKI and the Src kinase inhibitor AZD0530 and a triple combination for the synergistic treatment of breast cancer comprising an antioestrogen, an EGFR TKI and the Src kinase inhibitor AZD0530. | 02-03-2011 |
20110034477 | Crystalline Polymorph of Doxazosin Mesylate (Form IV) and Process for Preparation Thereof - Crystalline Form IV of doxazosin mesylate, a process for its preparation and uses thereof. | 02-10-2011 |
20110118277 | METHOD OF TREATING LIVER DISEASE - Treating diseased or damaged tissue, particularly the liver, using stem cells. The hepatic stem cell population of a subject suffering from disease or damaged tissue can be expanded by administering at least one regulator of the sympathetic nervous system. The regulator can be an adrenoceptor agonist or antagonist, adrenoceptor antagonists, prazosin, being particularly preferred. The invention also includes the use of agents which mobilize stem cells in the manufacture of medicaments for the treatment of diseased or damaged tissue. | 05-19-2011 |
20110124656 | Methods and Compositions for Treating Symptoms Associated with Post-Traumatic Stress Disorder using Cyclobenzaprine - The present invention relates to methods for the treatment or prevention of symptoms associated with post-traumatic stress disorder, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising a very low dose of cyclobenzaprine, alone, or in combination with an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor. | 05-26-2011 |
20110172241 | Benzazole analogues and uses thereof - The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, | 07-14-2011 |
20110195974 | METHODS OF TREATING INFLAMMATORY CONDITIONS WITH ADRENERGIC ANTAGONISTS - A method of treating inflammation and joint deterioration in mammals includes administering a therapeutically effective dose of alpha 1A receptor antagonists alone or in combination with a beta 2 adrenergic antagonists or beta 2 adrenergic antagonists and beta 2 adrenergic agonists. | 08-11-2011 |
20110207741 | Activation of the Renin-Angiotensin System (RAS) and Sudden Cardiac Death - Provided herein are methods of treating a medical condition in which RAS activation is increased. The method comprises the step of administering to a subject a c-Src inhibitor in an amount effective to treat the medical condition. The invention also provides a method of treating or preventing a cardiac arrhythmia. The method comprises the step of administering to the subject a c-Src inhibitor in an amount effective to treat or prevent the cardiac arrhythmia. The invention additionally provides a method of delaying the onset of sudden cardiac death. The method comprises the step of administering to the subject a c-Src inhibitor in an amount effective to delay the onset of SCD. Methods of augmenting gap junction function and methods of increasing Connexin 43 levels in a subject in need thereof are further provided. | 08-25-2011 |
20110224222 | CDK INHIBITOR FOR THE TREATMENT OF MESOTHELIOMA - The invention provides a low molecular weight ATP-competitive CDK inhibitor for use in the treatment of mesothelioma. The compound can be administered together with one or more cytotoxic or cytostatic agents. | 09-15-2011 |
20120046300 | Quinazoline Derivatives as Angiogenesis Inhibitors - The present invention relates to compounds of the formula I: | 02-23-2012 |
20120122881 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors. | 05-17-2012 |
20120238582 | QUINAZOLINE DERIVATIVES - Novel quinazolinamide derivatives of the formula (I), in which R | 09-20-2012 |
20120289514 | PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCY - Pharmaceutical composition for treating alcohol dependence in humans comprising two active ingredients:
| 11-15-2012 |
20130030003 | 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY-QUINAZOLINE-6-YLOXY]-1,4-DI- AZA-SPIRO[5.5]UNDECANE-5-ONE DIMALEATE, USE THEREOF AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF - The present invention relates to a compound of formula (I), | 01-31-2013 |
20130109698 | Small Molecule Inhibitors of Functions of the HIV-1 Matrix Protein | 05-02-2013 |
20130123270 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS - The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: | 05-16-2013 |
20130184286 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS - This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologically active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors. | 07-18-2013 |
20130190321 | METHODS AND COMPOSITIONS RELATING TO PROLIFERATIVE DISORDERS OF THE PROSTATE - Methods and kits for aiding in detection, assessment and treatment of a proliferative disorder of the prostate gland in a subject are provided according to aspects of the present invention which include assaying a first biological sample comprising prostate gland cells obtained from the subject for expression of one or more biomarkers selected from the group consisting of: alcohol dehydrogenase 1B, alcohol dehydrogenase 1C, alcohol dehydrogenase 4 and hepatocyte nuclear factor 1B; and determining, based on the expression of the one or more biomarkers in the sample that the subject has, or is at risk of having, a proliferative disorder of the prostate gland. | 07-25-2013 |
20130281461 | Spirocyclic Heterocycles Medicaments Containing Said Compounds, Use Thereof And Method For Their Production - The present invention relates to spirocyclic heterocycles of general formula (I) | 10-24-2013 |
20130289044 | Quinazoline Compounds as Sodium Channel Blockers - The invention relates to aryl substituted quinazolines of Formula I, and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, A, and R | 10-31-2013 |
20130338167 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives of Formula II, below: | 12-19-2013 |
20140163037 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS - Methods of inhibiting | 06-12-2014 |
20140303179 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors - This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT | 10-09-2014 |
20140336199 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors - This invention is related to the alkyl-piperazine-phenyl 4(3H)-quinazolinones compounds of general formula (I) below: | 11-13-2014 |
20140357646 | POLYMORPHS - The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament. | 12-04-2014 |
20140371233 | COMPOSITIONS AND METHODS FOR TREATING A -MODULATED DISEASE OR DISORDER OR IMPROVING COGNITION IN A SUBJECT - The present invention provides compositions and methods for treating and preventing an Aβ-modulated disease. In certain embodiments, the invention provides an inhibitor of Fyn tyrosine kinase, and methods of using the same. In certain embodiments, the inhibitor of the invention inhibits Aβ oligomer induced signaling and reduces or halts the progression of Alzheimer's Disease. | 12-18-2014 |
20140378469 | LKB1/STK11 DELETION IN MELANOMA AND RELATED METHODS - LKB1 mutation status and/or expression, YES expression and phosphorylation level; and/or CD24 expression are employed to predict melanoma prognosis and response to therapeutics. Inhibitors (including targeted inhibitors) of SRC family kinases (especially YES) are employed to treat melanoma. | 12-25-2014 |
20150018365 | Method of Treatment of Anxiety Disorder Comorbid with Depression Disorder - The present invention relates to a method for treating comorbid anxiety disorders and depression disorders, as well as for preventing depression disorders in individuals affected by anxiety disorders, by administering a therapeutically effective amount of the compound of general formula (I): | 01-15-2015 |
20150031705 | OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS - Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof. The active agents include, for example, alpha 1 antagonists, such as alpha 1a selective antagonists. | 01-29-2015 |
20150038514 | SODIUM AND CALCIUM SALTS OF DIHYDROQUINAZOLINE DERIVATIVE AND USE THEREOF AS ANTIVIRAL AGENTS - The invention relates to sodium and calcium salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treatment and/or prophylaxis of virus infections and to the use thereof for producing drugs for use in methods of treatment and/or prophylaxis of diseases, more particularly the use thereof as antiviral agents, more particularly against cytomegaloviruses. | 02-05-2015 |
20150045371 | Salts of a dihydroquinazoline derivative - The invention relates to besylate and tosylate salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treating and/or preventing virus infections, and to the use thereof to produce drugs for use in treating and/or preventing diseases, in particular use as antiviral agents, in particular against cytomegaloviruses. | 02-12-2015 |
20150080409 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT - Embodiments of the present disclosure, in one aspect, relate to a 2,4-diaminoquinazoline compound, pharmaceutical compositions including a 2,4-diaminoquinazoline compound, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like. | 03-19-2015 |
20150133460 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CAR- BOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS - This invention provides a compound of formula (I): | 05-14-2015 |
20150133461 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIVIRALLY ACTIVE DIHYDROQUINAZOLINE DERIVATIVE - The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses. | 05-14-2015 |
20150306101 | Pharmaceutical Combinations - A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. | 10-29-2015 |
20150320751 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor - The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: | 11-12-2015 |
20150328217 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE - The present invention relates to the use of CFTR correctors in the treatment of genetic disorders affecting striated muscle selected from sarcoglycanopathies, Brody's disease (BD) and the recessive forms of Cathecolaminergic Polymorphic Ventricular Tachycardia (CPVT). | 11-19-2015 |
20150335644 | COMPOSITIONS AND METHODS FOR TREATING SKIN CANCER ASSOCIATED DISEASES - The invention provides compositions and methods for treating skin cancer associated diseases. Specifically, the invention relates to topically administering a signaling pathway inhibitor or a related compound to treat pre-cancerous skin lesions, skin tumors, and their associated diseases or disorders. | 11-26-2015 |
20160008360 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | 01-14-2016 |
20160010157 | METHODS AND COMPOSITIONS RELATING TO PROLIFERATIVE DISORDERS OF THE PROSTATE | 01-14-2016 |
20160068495 | COMPOUND FOR PROMOTING APOPTOSIS OF CANCER CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND USES THEREOF - The present invention provides a compound of Formula (I) and a salt thereof, | 03-10-2016 |
20160106726 | PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCY - Pharmaceutical composition for treating alcohol dependence in humans comprising two active ingredients:
| 04-21-2016 |
20160145216 | AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL FORMULATIONS THEREOF FOR ORAL ADMINISTRATION - The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30° C. to 60° C., and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. | 05-26-2016 |